We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Hadebe, Bawinile![]() |
|
dc.contributor.author | Harry, Lerwine![]() |
|
dc.contributor.author | Gabela, Lerato![]() |
|
dc.contributor.author | Masikane, Siphelele![]() |
|
dc.contributor.author | Patel, Maryam![]() |
|
dc.contributor.author | Zwane, Sizwe![]() |
|
dc.contributor.author | Pillay, Venesen![]() |
|
dc.contributor.author | Bipath, Presha![]() |
|
dc.contributor.author | Cebekhulu, Nonhlanhla![]() |
|
dc.contributor.author | Nyakale, Nozipho E.![]() |
|
dc.contributor.author | Ramdass, Prathima![]() |
|
dc.contributor.author | Msimang, Mpumelelo![]() |
|
dc.contributor.author | Aldous, Colleen![]() |
|
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.contributor.author | Vorster, Mariza![]() |
|
dc.date.accessioned | 2024-12-13T06:44:16Z | |
dc.date.available | 2024-12-13T06:44:16Z | |
dc.date.issued | 2024-06 | |
dc.description | DATA AVAILABITY STATEMENT: The raw data supporting the conclusions of this article will be made available by the authors on request. | en_US |
dc.description.abstract | Please read abstract in article. | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sdg | SDG-09: Industry, innovation and infrastructure | en_US |
dc.description.sponsorship | The Nuclear Medicine Research Infrastructure (NuMeRi), the Discovery Foundation, and PentixaPharm AG, Berlin, Germany. | en_US |
dc.description.uri | https://www.mdpi.com/journal/diagnostics | en_US |
dc.identifier.citation | Hadebe, B.; Harry, L.; Gabela, L.; Masikane, S.; Patel, M.; Zwane, S.; Pillay, V.; Bipath, P.; Cebekhulu, N.; Nyakale, N.; et al. Chemokine Receptor-4 Targeted PET/CT Imaging with 68Ga-Pentixafor in Head and Neck Cancer—A Comparison with 18F-FDG and CXCR4 Immunohistochemistry. Diagnostics 2024, 14, 1375. https://doi.org/10.3390/diagnostics14131375. | en_US |
dc.identifier.issn | 2075-4418 (online) | |
dc.identifier.other | 10.3390/diagnostics14131375 | |
dc.identifier.uri | http://hdl.handle.net/2263/100007 | |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | en_US |
dc.subject | Pentixafor | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | SDG-09: Industry, innovation and infrastructure | en_US |
dc.subject | Head and neck squamous cell carcinoma (HNSCC) | en_US |
dc.subject | Positron emission tomography/computed tomography (PET/CT) | en_US |
dc.subject | Human immunodeficiency virus (HIV) | en_US |
dc.subject | Chemokine receptor 4 (CXCR4) | en_US |
dc.title | Chemokine receptor-4 targeted PET/CT imaging with 68Ga-Pentixafor in head and neck cancer—a comparison with 18F-FDG and CXCR4 immunohistochemistry | en_US |
dc.type | Article | en_US |